Possible side effects with therapeutic probe drug doses included hypotension with debrisoquin (CYP2D6 probe), hypoglycemia with tolbutamide [81] (CYP2C9 probe), bleeding risk with warfarin (CYP2C9 probe, requiring co-administration of vitamin K) and gastrointestinal side effects and sedation with mephenytoin (CYP2C19) [82]. This evidence concerns the gene CYP2C9 and Hypoglycemia.